Related Experiment Video
Updated: Jun 3, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Update of chronic hepatitis B
1Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8887, USA.
Insights
Advances in chronic hepatitis B (CHB) treatment are reviewed. While many patients remain undiagnosed, new insights into Hepatitis B e antigen (HBeAg) seroconversion durability and Hepatitis B surface antigen (HBsAg) kinetics offer improved understanding and potential for better outcomes.
Area of Science:
- Hepatology and Viral Hepatitis Research
- Clinical Infectious Diseases
- Pharmacology and Therapeutics
Background:
- A significant gap exists in the diagnosis and treatment of chronic hepatitis B (CHB) in the US, with an estimated two-thirds of patients unidentified.
- Current CHB treatment guidelines include seven approved medications for adults and four for children.
- Lack of awareness among medical professionals and at-risk populations contributes to underdiagnosis and undertreatment of CHB.
Purpose of the Study:
- To review recent developments in the treatment of chronic hepatitis B (CHB).
- To synthesize findings from published articles between December 2009 and November 2010 regarding CHB therapies.
Main Methods:
- Systematic review of published literature on CHB treatment.
- Analysis of data on approved medications, treatment endpoints, and emerging biomarkers.
Main Results:
- Hepatitis B e antigen (HBeAg) seroconversion remains a key endpoint, but its durability with nucleoside analogue therapy is still under investigation.
- Hepatitis B surface antigen (HBsAg) seroclearance has been observed in some patients receiving antiviral therapy.
- HBsAg quantitation and kinetics are emerging as potential predictors of treatment response and indicators of CHB natural history.
Conclusions:
- Significant progress has been made in understanding the durability of HBeAg seroconversion.
- The clinical importance of serum HBsAg kinetics is increasingly recognized in both treatment-naive and treated CHB patients.
- Enhanced education programs are crucial to raise public and professional awareness of CHB's public health significance.
Purpose Of Review:
We review here new developments in chronic hepatitis B (CHB) treatment, based on review of published articles between December 2009 and November 2010.
Recent Findings:
It is estimated that two-thirds of US CHB patients have not been identified, evaluated and appropriately treated, largely due to lack of knowledge and awareness of CHB among medical professionals and at-risk populations. Seven medications have been approved to treat CHB in adults, but only four medications have been approved to treat CHB in children.Hepatitis B e antigen (HBeAg) seroconversion is still an important treatment endpoint in HBeAg-positive patients. Durability of nucleoside analogue treatment-related HBeAg seroconversion is still questionable. Hepatitis B surface antigen (HBsAg) seroclearance has been achieved in some patients with antiviral therapy. HBsAg quantitation and kinetics is now being studied to determine its role in the natural history of CHB and whether these measures may predict future response to current antiviral therapy.
Summary:
Great advances have been made in understanding the HBeAg seroconversion durability. The clinical significance of serum HBsAg kinetics has been recognized in naive CHB patients and patients with antiviral therapy. More education programs are needed to improve the public awareness of the importance of CHB to the health of whole population.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis I: Introduction
Chronic Pancreatitis II: Collaborative Care
Assessment:
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

